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Abstract
The authors have developed and validated some chromatographic methods with 
the aim of quantifying drugs as drug substance and drug product, suitable for sta-
bility and quality control studies, as at original products as at its remainder doses. 
The stability of a pharmaceutical is defined by its resistance to different chemical, 
physical, and microbiological reactions that may change their original properties. 
The stability of a pharmaceutical product is closely related to its potency; there-
fore, whether the compounds are degraded, a decrease of the therapeutic effect or 
changes in their toxicological properties can be produced, affecting their efficacy 
and safety, which becomes important to maintain a stable pharmaceutical product 
and to have the analytical tools to demonstrate stability. Therefore, stability-indi-
cating methods are required to the quality control of pharmaceuticals. Analytical 
methods presented here are useful stability-indicating methods to analyze drugs 
and have adequate linearity, precision, accuracy, selectivity, and LOD/LOQ values. 
The examples presented here are stability-indicating methods since they allow the 
determination of drugs in the presence of their degradation products, according to 
the International Conference on Harmonization (ICH) guidelines.




Pharmaceutical stability is the capability of a dosage form included in a specific 
container to suffer minimum or no degradation during its transport, storage, and 
use. It can be influenced by intrinsic factors such as the chemical structure of the 
drug and environmental conditions, as temperature, humidity, oxygen, and light. 
Each ingredient, whether therapeutically active or pharmaceutically necessary 
(excipients), can affect the stability. The primary environmental factors that can 
reduce stability include exposure to adverse temperatures, light, humidity, oxygen, 
and carbon dioxide. Various types of reactions can cause chemical degradation of 
pharmaceuticals, which usually cause loss of active drug content and formation 
of degradation products. These reactions are hydrolysis, oxidation, photolysis, 
dehydration, isomerization, polymerization, decarboxylation, absorption of carbon 
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dioxide, and radiation-induced reactions. The most common reactions are hydro-
lysis and oxidation. Chemical degradation may result in a loss of potency or an 
increase in drug toxicity, so that the clinical use of a medicine must be unacceptable 
if the degradation is relatively great. When a drug dosage form is altered (by disso-
lution, pulverization, or addition to other materials) or the environment of the drug 
is modified by changes in storage conditions, the stability of a drug may be affected 
[1–4]. Stability is often expressed in quantitative terms as the shelf life, that is, the 
time from manufacture to the original potency or content of active constituent has 
been reduced by 10%. For most products, this 10% limit for chemical degradation is 
generally recognized as the minimum acceptable potency level [5].
Stability testing forms an important part of the process of drug development; 
its purpose is to provide evidence on how the quality of drug substance or drug 
product varies with time under the influence of a variety of environmental factors, 
such as humidity, temperature, and light, to establish a retest period for the drug 
substance or a shelf life for the drug product, and to recommended storage condi-
tions. The studies are designed to include testing of attributes susceptible to change 
during storage and are likely to influence quality, safety, and efficacy.
Testing primarily covers physical, chemical, and microbiological attributes:
• Physical: appearance, melting point, water content, clarity and color of 
solution, pH, dissolution and disintegration characteristics, viscosity, crystal 
modification, or particle size
• Chemical: assay, degradation products, related substances, and residual 
solvents
• Microbial: growth in microorganisms and efficiency of preservative contents 
such as antioxidants and antimicrobial preservatives
Stability studies on active substances and manufactured dosage forms 
are conducted by means of accelerated, long-term studies and stress testing. 
Accelerated and long-term tests are developed at specific temperatures and 
relative humidity representing storage conditions experienced in the distribution 
chain of the climatic zone(s) of the country or region of the world concerned. 
The aim of these studies is to determine the shelf life of the product. Stress 
studies are conducted to elucidate the intrinsic stability of the drug substance 
and are normally carried out under more severe conditions than those used for 
accelerated testing. Stress testing is the main tool that is used to predict stability 
problems, with the aim to anticipate the behavior of the drug substance when 
using it as a drug product [6, 7]. From the results of stress testing, useful infor-
mation can be obtained for the manufacturing process, packaging development, 
and appropriate storage conditions of the products in order to avoid degradation 
[7]. The chemical stability is evaluated by testing the quantity of drug at differ-
ent times during the storage [2, 3].
1.2 Pharmaceutical quality control/pharmaceutical assurance
The term drug quality control refers to the sum of all procedures undertaken to 
ensure the identity and purity of a particular pharmaceutical, as active ingredient 
and dosage forms. These procedures involve the identification of a pharmaceutical 
substance; potency, usually 90–110% of the labeled amount; uniformity of color; 
shape; size in dosage forms; bioavailability; and stability, in concordance with 
the requirements of pharmacopoeial monographs (International Pharmacopeia, 
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European Pharmacopeia, US Pharmacopeia, British Pharmacopeia, National 
Pharmacopeia), and it was carried out in quality control laboratories [8, 9].
Quality control (QC) is an essential operation of the pharmaceutical industry to 
guarantee a safe and effective product. QC measurements include stability testing 
of the drug formulation, dissolution testing, and analysis of raw material products 
majorly.
QC is the term usually employed; however, there are two terms about drug or 
pharmaceutical quality control:
1.2.1 Pharmaceutical quality assurance (QA)
Quality assurance involves the development and implementation of a system 
that ensures that the pharmaceutical is safe; effective, with standard quality; and 
acceptable to the patient.It is achieved with systematic activities implemented in a 
quality system to ensure that the requirements for product development are fulfilled 
and involve appropriate storage, distribution, monitoring and use by prescribers, 
dispensers and consumers.
1.2.2 Pharmaceutical quality control (QC)
All of activities are required to control the processes associated with the product 
manufacture and evaluation of product quality at various steps from raw materials 
to the final packaged product that reaches the consumer.
In this way, good manufacturing practices (GMPs) are part of the quality assur-
ance activities that ensure that products are consistently produced and controlled to 
the quality standards appropriate to their intended use and required by the drug regu-
latory authorities, for example, personnel, facilities, packaging, and quality control.
Assuring quality involves some aspects, as:
• Active ingredients are safe and efficient
• Providers have acceptable quality standards
• Active ingredients and pharmaceutical in dosage forms are monitored to meet 
quality standards
• Pharmaceutical packaging is optimal and protects from degradation
• Storage conditions of pharmaceutical are optimal
• Transportation conditions are adequate
• Product quality concerns are reported and monitored
Low quality medicines can produce a decrease of their therapeutic effect or 
changes in their toxicological properties, which can cause a prolongation of illness 
and even death, and an increase in health costs.
1.3 Stability testing for drug substances and drug products (pharmaceuticals)
Stability testing predicts behavior of a drug or pharmaceutical with any physi-
cal, chemical, or microbiological changes, with the aim to assess their security and 
efficacy and to establish their shelf life and optimal storage conditions [10–21].
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1.4 Stress testing (forced degradation studies)
Stress testing is an important part of drug development process because it can 
help to establish the degradation pathways and the intrinsic stability of the molecule 
and help to develop stability-indicating methods. Stress testing helps to anticipate 
the behavior of drug substance and drug products and their mechanisms (hydro-
lysis, oxidation, thermolysis, or photolysis) and identify the degradation products, 
including their chemical structure. These studies are a regulatory requirement and 
scientific necessity during drug development, with the aim to generate more stable 
formulations. Stress testing includes the effect of temperatures and other appropri-
ate conditions such as humidity, light exposition, and others. Because it is faster and 
less expensive than conducting longer-term storage tests, the technique is used for 
rapid selection and elimination tests. The samples generated from forced degrada-
tion can be used to develop the stability-indicating method that can be applied 
later for the analysis of samples generated from accelerated and long-term stability 
studies [1–4, 22].
The nature of the stress testing depends on the individual drug substance and 
the type of pharmaceutical product involved. Stress testing is likely to be carried 
out on a single batch of the active pharmaceutical ingredient. Generally, the goal of 
stress testing is to facilitate an approximate 5–20% degradation of the sample under 
any given condition, so as to avoid any secondary reactions. It should include the 
effect of temperature, above that for accelerated testing (in 10°C increments, e.g., 
50°C, 60°C, etc.), humidity (75% RH or greater), oxidation, photolysis, and the 
susceptibility to hydrolysis on the active pharmaceutical ingredient (API) [7, 23].
Stress testing is likely to be carried out on a single batch of the active pharma-
ceutical ingredient. It should include the effect of temperature (in 10°C increments, 
e.g., 50°C, 60°C) above that for accelerated testing, humidity (25°C, 75% RH or 
greater) where appropriate, oxidation, and photolysis on the active pharmaceuti-
cal ingredient (API). The testing must also evaluate the susceptibility of API to 
hydrolysis and its photostability. Significant change for a drug substance is defined 
as failure to meet its specification [24].
2. Analytical method validation as the first step in drug quality control
To  evaluate the stability of drug substances or drug product, qualitative and 
quantitative methods should be used, to allow evaluate the physical, chemical, 
biological and microbiological stability.
In relation to chemical stability, the assay methods chosen should be those 
indicative of stability. These methods will resolve all degradation products from the 
parent compounds and ideally from each other, so that the active compound content 
can be accurately measured without interference from degradation products [7]. 
The most used analytical method in drug quality control is still high-performance 
liquid chromatography (HPLC) coupled with UV or fluorescence detection. Other 
useful methods are LC coupled with mass spectrometry (MS) or with diode array 
(LC/DAD), refractive index (RI), electrochemical, light-scattering detection, size 
exclusion chromatography (SEC), UPLC, capillary electrophoresis (CE), and gas 
chromatography (GC). High-performance thin-layer chromatography (HPTLC) has 
the advantages of its fastness, solvent economy, and high throughput of samples. 
Chromatography of samples simultaneously with standards is another advantage, 
allowing to run up to 60 spots simultaneously. Sensitivity of HPTLC is normally in 
the range of nanograms in absorbance and picograms in fluorescence mode  
(www.europeanpharmaceuticalreview.com.Access: 30-10-2018; [25]).
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2.1 Importance of analytical method validation used in drug quality control
Analytical method validation is an integral part of any good analytical practice. 
The results from a method validation procedure can be used to judge the quality, 
reliability, and consistency of analytical results. Analytical methods should be 
validated or verified, and the accuracy as well as the precision (standard devia-
tions), limit of detection (LOD) and limit of quantification (LOQ ), sensitivity, 
linearity, and applicability should be recorded. The tests for related compounds or 
products of decomposition should be validated to demonstrate that they are specific 
to the product being examined and are of adequate sensitivity. Validated analytical 
methods play a major role in achieving the quality and safety of the final product 
especially in the pharmaceutical industry [26]. Among the FDA, some other useful 
protocols can be addressed by the International Council on Harmonization (ICH), 
current good manufacturing practice (CGMP), US Pharmacopeia (USP), Turkish 
Pharmacopeia, European Medicines Agency (EMA), International Organization 
for Standardization (ISO), Association of Analytical Chemists (AOAC), and the 
American Public Health Association [3, 6, 24, 26, 27–31].
2.2 Some stability-indicating methods developed and validated by authors
The authors have developed and validated some chromatographic methods suit-
able for quality control studies of bulk drugs and drugs in dosage forms.
2.3 Chemical stability of haloperidol injection by high-performance thin-layer 
chromatography
Enalapril is an angiotensin-converting enzyme (ACE) inhibitor. Enalapril (Figure 1) 
is a prodrug and has little pharmacological activity until hydrolyzed in the liver to 
enalaprilat (Figure 2). Enalapril is the ethyl ester of enalaprilat [1, 4, 32–35].
Enalapril is used alone or in combination with other classes of antihypertensive 
agents for the management of hypertension. It is reported that enalapril drug sub-
stance or pharmaceutical preparation degrades to two major degradation products, 
enalaprilat and diketopiperazine (DKP) derivative, under different storage condi-
tions, resulting in drug loss and potency reduction [1, 4, 32–35].
A stability-indicating high-performance thin-layer chromatographic (HPTLC) 
method was developed and validated by the authors, with the aim of determination 
of enalapril maleate in tablets.
Figure 1. 
Chemical structure of enalapril.
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Figure 3. 
Selectivity of the method. A study with enalapril, enalaprilat, and DKP. Peak observed: enalaprilat, 
enalapril, and DKP. Rf, retarding factor; AU, absorbance unit.
Chromatographic separation was achieved on precoated silica gel F 254 
HPTLC plates using a mixture of 1-butanol, glacial acetic acid, and water (12:3:5, 
v/v) as a mobile phase. Quantitative analysis was carried out at a wavelength of 
207 nm. The method exhibited an adequate linearity with a correlation coefficient 
of 0.998, over the concentrations range of 200 to 1200 ng/μL (200 to 1200 ng/
band). Limit of detection (LOD) was 23.78 ng/ band, and limit of quantification  
(LOQ ) was 72.01 ng/band. The method exhibited a good precision, with an intra-
assay variation between 1.14 and 1.43% and an inter-assay variation between 1.27 
and 3.67%; an adequate accuracy, good selectivity (Rf was 0.52 for enalaprilat, 
0.62 for enalapril, and 0.82 for diketopiperazine (DKP) , a degradation product. 
Also, the selectivity between enalapril and hydrochlorothiazide, the more com-
mon compounds in the commercial mixtures of enalapril, was studied. The Rf 
was 0.52 for enalaprilat, 0.62 for enalapril, and 0.83 for hydrochlorothiazide 
(Figures 3 and 4) [36].
Stability-indicating capability of the HPTLC assay was studied by forced decom-
position of 5 mL of a solution of enalapril 1 mg/mL, with 10 mL of 0.1 N hydrochlo-
ric acid, 10 mL of 0.1 N sodium hydroxide, and 10 mL of 3% H2O2. The mixtures 
Figure 2. 
Chemical structure of enalaprilat.
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with NaOH and with HCl were heated on hot plates at 60°C for 60 min. The mixture 
with H2O2 was stored at room temperature (25°C) for 60 min. Then, each mixture 
was diluted with ethanol to 100 ng/μL and analyzed. Also, stability-indicating 
capability of the assay was proven by conducting forced degradation conditions of 
UV and VIS radiation on enalapril standard, as solution of 100 ng/μL. Degradation 
was found significantly in basic stress condition only, during the time of the study. 
The degradation products for enalapril mentioned in the literature are enalaprilat 
and DKP [34, 36]. The degradation product was well resolved from the main peak, 
proving the stability-indicating power of the method (Figure 5) [37].
2.4 Validated instrumental planar chromatographic method for quantification 
of fluphenazine hydrochloride in injections
Fluphenazine (Figure 6) is a phenothiazine antipsychotic agent. The drug is a 
propylpiperazine derivative of phenothiazine and is structurally similar to perphen-
azine but differs from perphenazine in the substitution of a trifluoromethyl group 
for chlorine at the two positions of the phenothiazine nucleus.
Drug therapy with fluphenazine is integral for the management of acute psy-
chotic episodes with violent behavior in patients with schizophrenia and generally is 
required for long-term stabilization to improve symptoms between episodes and to 
minimize the risk of recurrent acute episodes.
Figure 4. 
Selectivity of the method. A study with enalapril, enalaprilat, and hydrochlorothiazide. Peak observed: 
enalaprilat, enalapril, and hydrochlorothiazide. Rf, retarding factor; AU, absorbance unit.
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Other uses for fluphenazine are for the treatment of mania, bipolar disorder, 
severe anxiety, and behavioral disturbances. Fluphenazine is administered as the 
hydrochloride by mouth or intramuscular injection; longer-acting decanoate or 
enantate esters of fluphenazine are given by intramuscular or sometimes subcuta-
neous depot injection [32, 35, 43].
Fluphenazine hydrochloride, decanoate, and enantate are all sensitive to light. 
Therefore, it is very important to determine the quantity of fluphenazine in its 
dosage forms because in the presence of light, photolysis occurs rapidly, resulting in 
drug loss and potency reduction [2, 4, 32–35].
Chromatographic separation was done on precoated silica gel F 254 HPTLC 
plates. The mobile phase consisted of methanol/purified water (9:1, v/v). 
Densitometric analysis was carried out at 306 nm. The calibration curves were 
linear in the range of 100 ng/μL to 500 ng/band with a correlation coefficient of 
0.998. The limit of detection (LOD) and limit of quantification (LOQ ) were found 
to be 1.45 ng and 4.40 ng, respectively. The intra-assay and inter-assay precisions, 
expressed as the relative standard deviation (RSD), were in the range of 0.73–1.77% 
and 1.18–1.86%, respectively. The recovery of fluphenazine hydrochloride was 
between 98.29 and 101.53%, with a RSD not higher than 1.87%. The method was 
selective for fluphenazine hydrochloride from the preservatives of the injections 
(Rf for fluphenazine hydrochloride was 0.33, whereas parabens run to the solvent 
front) (Figures 7 and 8) [38].
Figure 6. 
Chemical structure of fluphenazine.
Figure 5. 
A study at forced degradation of enalapril with 0.1 N NaOH. Peak no. 1, enalaprilat; peak no. 2, enalapril; 
and peak no. 3, DKP. Axis X: retarding factor (Rf). Axis Y: absorbance unit (AU).
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Drug content was found to be within the limits (95–110% of the labeled content 
of the formulations) of the prescribed value, when the method was applied to 
quantify fluphenazine hydrochloride in real pharmaceutical samples.
Stability-indicating capability of the HPTLC assay was studied by forced 
decomposition of 5 mL of a solution of fluphenazine 1 mg/mL, with 10 mL of 0.1 N 
hydrochloric acid, 10 mL of 0.1 N sodium hydroxide, and 10 mL of 3% H2O2. The 
mixtures with NaOH and with HCl were heated on hot plates at 60°C for 60 min. 
The mixture with H2O2 was stored at room temperature (25°C) for 60 min. Then, 
each mixture was diluted with ethanol to 100 ng/μL and analyzed.
Also, stability-indicating capability of the assay was proven by conducting 
forced degradation conditions of UV and VIS radiation on fluphenazine standard, 
as solution of 100 ng/μL.
One degradation product was found after treatment of fluphenazine with HCl, 
and two degradation products were found after treatment with NaOH. Rf for 
fluphenazine was 0.30, whereas Rf for degradation product with HCl was 0.01, and 
Rf for degradation products with NaOH were 0.03 and, 0.23 respectively (Figure 9). 
None degradation product was found with H2O2.
When the drug was exposed to force degradation with VIS radiation, another peak 
different from the peak of fluphenazine was found; therefore, it could be a degradation 
Figure 7. 
Selectivity of the method. A study with parabens. Peak observed: fluphenazine. Rf, retarding factor;  
AU, absorbance unit.
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product. Rf for fluphenazine = 0.30 and Rf for degradation product = 0.56 (Figure 10) 
[38]. One of the products of photolysis mentioned in literature is a sulfoxide [2].
2.5 Stability-indicating HPLC method for quantification of risperidone in tablets
Risperidone is a benzisoxazole derivative (Figure 11), a second-generation anti-
psychotic agent, that is chemically unrelated to other antipsychotic drugs. It is used 
for the treatment of schizophrenia, bipolar disorder, and irritability in children with 
autism. The major impurity products in the dosage forms, including degradation 
Figure 8. 
Picture (video store, CAMAG) of plate at selectivity with parabens. Tracks 1–3, fluphenazine hydrochloride; 
tracks 4–6, fluphenazine hydrochloride + methylparaben; tracks 7–9, fluphenazine hydrochloride + 
propylparaben; and tracks 10–12, fluphenazine hydrochloride + methylparaben + propylparaben. Bands of 
parabens can be observed at the solvent front.
Figure 9. 
Degradation study of fluphenazine with HCl, with NaOH, and with H2O2. Tracks 1–3 (from bottom side to 
the upper side), fluphenazine; tracks 4–6, fluphenazine + HCl; tracks 7–9, fluphenazine + NaOH; and tracks 
10–12, fluphenazine + H2O2. Rf peak fluphenazine = 0.30. Other peaks at tracks 4–9: degradation products.  
Rf, retarding factor; AU, absorbance unit.
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products, described in USP are Z-oxime, bicyclo risperidone, and cis-risperidone 
N-oxide [3]. Some degradation products found in work investigations had been 
9-hydroxyrisperidone and N-oxide of risperidone [32–35].
A stability-indicating LC method was developed and validated for the determi-
nation of risperidone in tablets. Quantitation was achieved by LC/DAD at 294 nm 
over the concentration range of 25.00–250.00 μg/mL. Mobile phase was a mixture 
of water, glacial acetic acid 0.5%, triethylamine 0.8%, and acetonitrile (65.00, 
0.32, 0.52, 34.16, v/v), using a Purospher STAR RP-18e 250 × 4.5 mm (5 μ) column 
(Merck KGaA, Darmstadt, Germany) and paroxetine as internal standard. The 
method exhibited an adequate linearity, with a correlation coefficient of 0.999, 
selectivity, precision (RSD ≤ 0.847%), and accuracy (recoveries from 99.55 to 
101.35%).
Risperidone was subjected to the stress conditions of oxidative, acid, base, ther-
mal, and photolytic degradation. Risperidone was found no degrade in basic or acid 
stress conditions, neither in thermal stress exposition (50, 70, and 100°C) nor at 
visible or UV stress conditions, during the time of the study. Only two degradation 
products were observed with peroxide oxidation, well resolved from analyte peak, 
proving the stability-indicating power of the method. The drug was highly labile to 
hydrogen peroxide (3%) at room temperature. After 6 hours, steep fall in the drug 
peak area was observed. Major degradation products appeared at tR = 2.0 and tR = 5.3. 
These peaks were resolved from risperidone (tR = 3.5) (Figure 12). Risperidone was 
degraded to 35.00% when it was exposed to room light for 8 days, and it was degraded 
Figure 10. 
Degradation study of fluphenazine with VIS radiation. Peak no. 1 (from left to right), fluphenazine, and peak 
no. 2, degradation product. Rf, retarding factor; AU, absorbance unit.
Figure 11. 
Chemical structure of risperidone.
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to 17.00% when it was exposed to 80°C for 6 hours (Figure 13) [39]. One degradation 
product found in work investigations had been N-oxide of risperidone [3, 32].
2.6 Stability HPLC methods for stress testing studies of quinapril/
hydrochlorothiazide and candesartan/hydrochlorothiazide
Quinapril hydrochloride (QUIN), hydrochlorothiazide (HCTZ), and candesar-
tan cilexetil (CAN) are drugs that are widely used in the management of a highly 
prevalent disease such as hypertension. They are used alone or as combination 
therapy; the association of QUIN/HCTZ and CAN/HCTZ is used as combina-
tion therapy in the treatment of patients whose blood pressure is not adequately 
controlled with any of the substances alone. QUIN (Figure 14) is an angiotensin-
converting enzyme (ACE) inhibitor used alone or in combination with other classes 
of antihypertensive agents; it is a prodrug and has little pharmacological activity 
until hydrolyzed in the liver to quinaprilat [32, 34]. HCTZ (Figure 15) is a thiazide 
diuretic and antihypertensive agent [32], and CAN (Figure 16) is an angiotensin II 
receptor antagonist (AT1) used alone or in combination with other classes of anti-
hypertensive agents; CAN is a prodrug and has little pharmacological activity until 
hydrolyzed during absorption in the gastrointestinal tract to candesartan [32, 34]. 
All three drugs have chemical structures susceptible to degradation; therefore, it is 
important to determine their stability.
In order to assess the chemical stability of a compound, it is very important to 
have the appropriate analytical method, i.e., they must be stability-indicating [3]. 
The main target while developing these methods was to have a single method for 
separation between QUIN/HCTZ or CAN/HCTZ and their degradation products. 
A stability- indicating LC methods with DAD and ELSD detection were developed 
by the authors for the simultaneous determination of CAN/HCTZ [40] and QUIN/
HCTZ [41].
Figure 12. 
Study at forced degradation of risperidone with 3% H2O2 at room light for 8 days and with 3% H2O2 at 80°C 
for 6 h. Peak 1 (tR = 2.0): degradation product. Peak 2 (tR = 3.5): risperidone. Peak 3 (tR = 5.3): degradation 
product.
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Figure 13. 
Risperidone degradation at 3% H2O2 exposition.
Figure 14. 
Chemical structure of quinapril.
Figure 15. 
Chemical structure of hydrochlorothiazide.
Figure 16. 
Chemical structure of candesartan.
Quality Management and Quality Control - New Trends and Developments
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2.6.1 CAN/HCTZ
HPLC analyses were carried out on a Purospher® RP-18 column 
(125 mm × 4 mm, 5 μm; Merck KGaA, Darmstadt, Germany). Valsartan was 
used as internal standard (IS) at 70.0 μg min−1. For LC/DAD method, the mobile 
phase consisted of acetonitrile (A) and phosphate buffer (pH 6.0; 0.05 M) 
(B) in a gradient mode. The flow rate was set to 1 mL min−1, with UV detector 
wavelength fixed at 225 nm, and the column temperature was set at 30°C. For 
LC/ELSD method, the mobile phase consisted of acetonitrile (A) and water 
with acetic acid (0.175 M) and triethylamine (0.06 M) (pH 4.1) (B) in a gradient 
mode. The flow rate was set to 0.8 mL min−1 and the column temperature was 
set at 35°C. ELSD evaporation temperature was set at 40°C, the gain was 7, and 
the nebulizer gas pressure was kept at 3 bar. The response with ELSD was fitted 
to a power function and the DAD response by a linear model over a range of 
32–160 μg/mL for CAN and 25–125 μg/mL for HCTZ. The precision and accuracy 
of the methods were similar, with RSD below 3.0% and recovery between 98.1 
and 103.9%. The drugs were subjected to stress conditions of hydrolysis, oxida-
tion, photolysis, humidity, and temperature. Both drugs were mainly degraded 
by hydrolysis, showing the formation of one degradation product for HCTZ 
identified by MS/MS as 4-amino-6-chloro-1,3-benzendisulfonamide (DSA) and 
two for CAN cilexetil identified as candesartan and desethyl candesartan cilex-
etil. The degradation products were satisfactory separated from the main peaks 
and from each other as shown in Figure 17.
Figure 17. 
(1) degradation product of HCTZ (DSA), (2) HCTZ, (3) alkaline degradation product of CAN 
(candesartan), (4) IS (valsartan), (5) acidic and neutral degradation product of CAN (desethyl candesartan 
cilexetil), and (6) CAN.
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2.6.2 QUIN/HCTZ
HPLC analyses were carried out on a Chromolith® High Resolution RP-18 
column (100 mm × 4.6 mm). For LC/DAD method, the mobile phase consisted of 
acetonitrile (A) and phosphate buffer (pH 3.0; 0.01 M) (B) in a gradient mode. The 
flow rate was set to 1.5 mL min−1 with UV detector wavelength fixed at 215 nm, 
and the column temperature was set at 30°C. For LC/ELSD method, the mobile 
phase consisted of acetonitrile (A) and water with acetic acid (0.086 M) and 
triethylamine (0.007 M) (pH 3.3) (B) in a gradient mode. The flow rate was set 
to 1.0 mL min−1, and the column temperature was set a 35°C. ELSD evaporation 
temperature was set at 40°C, the gain was 7, and the nebulizer gas pressure was kept 
at 3 bar. The analytes were eluted within 7 minutes in both methods. The response 
Figure 18. 
Chromatogram with DAD and ELSD: (1) DSA, (2) HCTZ, (3) quinaprilat, (4) QUIN, and (5) DKP.
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with DAD was linear, and the response with ELSD was fitted to a power function, 
for quinapril and hydrochlorothiazide concentrations of 20–160 μg mL−1 and 
12.5–100 μg mL−1, respectively. DAD method achieved better precision than ELSD 
method, the LOQ of DAD was lower, and the accuracy of the methods was similar. 
Quinapril was subjected to hydrolytic, oxidative, thermal, humidity, and photolytic 
stress conditions. Quinapril was degraded by hydrolysis and thermal stress, show-
ing the formation of quinaprilat and quinapril diketopiperazine as degradants, 
which were identified by MS/MS. Degradation products were well resolved from 
the main peaks and from each other, proving the stability-indicating power of the 
methods as shown in Figure 18.
2.7 Stability-indicating HPLC method for quantification of vortioxetine in bulk 
and tablets
Vortioxetine hydrobromide (Figure 19) is a serotoninergic novel antidepres-
sant with multiple pharmacologic activities [32, 41], approved by the US Food 
and Drug Administration in 2013 [42] for the treatment of major depressive 
disorder in adults. It is a phenylpiperazine derivative. Although the precise 
mechanism of action is not fully understood, it is thought to be related to 
enhancement of serotoninergic activity in the central nervous system through 
inhibition of serotonin reuptake [32, 42]. It has a chemical structure susceptible 
to degradation; therefore, it is important to determine its stability by suitable 
analytical methods.
A simple HPLC method with photodiode array detection (DAD) was developed 
and validated by the authors [43], for determination of VOR in bulk and tablets, 
in the presence of its major degradation products. A C-18 column was used, with 
mobile phase consisting of acetonitrile and water with acetic acid and triethylamine 
in isocratic elution mode, with detection at 228 nm and 1.0 mL/min flow rate. 
Under these conditions, all the analytes were eluted within 15 min. Bromazepam 
was used as internal standard at 25 μg/mL. The assay was linear in the 25–125 μg/
mL concentration range. For precision, the RSD was lower than 1.8%, the recovery 
was between 100.0 and 101.6%, and the method demonstrated adequate selectiv-
ity (Figure 20). The drug was subjected to oxidative, hydrolytic, and photolytic 
stress conditions, showing significant degradation under oxidation with complete 
degradation after 1 day of stress, and was stable under acid, alkaline, neutral, and 
photolytic conditions. One main oxidative degradation product was formed, which 
was identified by ESI-MS/MS as the benzylic alcohol of VOR (Figure 21).
Figure 19. 
Chemical structure of vortioxetine.
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Figure 20. 
Chromatogram of VOR, internal standard (IS), and oxidative degradation product (DP).
Figure 21. 
The mass spectrum of vortioxetine standard (a) and oxidative degradation product (b).
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3. Conclusions
The stability of a pharmaceutical is defined by its resistance to different chemi-
cal, physical, and microbiological reactions that may change their original proper-
ties. The stability of a pharmaceutical product is closely related to its potency; 
therefore, whether the compounds are degraded, a decrease of the therapeutic 
effect or changes in their toxicological properties can be produced, affecting their 
efficacy and safety, which becomes important to maintain a stable pharmaceuti-
cal product and to have the analytical tools to demonstrate stability. Therefore, 
stability-indicating methods are required to the quality control of pharmaceuticals.
The examples presented here are stability-indicating methods since they allow 
the determination of drugs in the presence of their degradation products, according 
to the International Conference on Harmonization (ICH) guidelines.
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